![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Krystal Biotech Inc | NASDAQ:KRYS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-4.71 | -2.65% | 173.00 | 170.27 | 184.00 | 180.72 | 172.45 | 177.83 | 477,341 | 22:30:00 |
Poster presentation details are as follows:
Title: An HSV-1-Based Vector Platform for Localized Delivery to the Posterior of the EyePresenter: Haley Nicole CartwrightDate and Time: May 7, 2024 from 3:30PM to 5:15PM PTPosterboard Number: B0022Abstract Number: 3978 - B0022
The poster will be available to conference attendees. Following the presentation, the poster will also be available to view online on the Investor section of the Company’s website.
About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the first medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and X (formerly Twitter).
CONTACTInvestors and Media: Stéphane Paquette, PhDKrystal Biotechspaquette@krystalbio.com
1 Year Krystal Biotech Chart |
1 Month Krystal Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions